Of the estimated 350 million people living with MASH globally, fewer than 13 million are receiving any treatment, a treatment gap that makes the disease one of the most commercially consequential in hepatology. Madrigal Pharmaceuticals, which already markets Rezdiffra (resmetirom) for MASH with moderate-to-advanced fibrosis, is now betting that RNA interference can extend its reach into patient populations its approved oral thyroid receptor beta agonist does not fully address. The company and Suzhou Ribo Life Science announced on July 1, 2026 that their collaboration has produced its first candidate drug nomination, triggering immediate IND-enabling studies.
The strategic logic here is not subtle. Madrigal holds a strong commercial position in MASH with Rezdiffra, but the disease is mechanistically complex and a single drug rarely saturates a $7.8 billion-plus global market. Layering in a liver-directed siRNA program allows Madrigal to pursue distinct biological targets while leaning on Ribo’s delivery platform, which is specifically engineered for hepatic tissue. The partnership covers multiple preclinical assets, so this first nomination is a proof-of-execution moment rather than the full picture of what the collaboration could produce.
Ribo’s contribution is meaningful on its own terms. Suzhou Ribo has built vertically integrated siRNA discovery and delivery capabilities, and its subsidiary Ribocure Pharmaceuticals is structured explicitly for global clinical development. That organizational design matters: China-based platforms with credible Western clinical infrastructure are no longer a novelty in RNA therapeutics, but the pairing with a company that already navigated a MASH Phase 3 and won FDA approval compresses the institutional learning curve considerably. The candidate moves from nomination to IND-enabling studies without a gap, which reflects genuine alignment between the two organizations on timeline and priority.
The number to watch now is how quickly IND-enabling data translate into a first-in-human filing. Rezdiffra’s Phase 3 enrollment exceeded 950 patients, and Madrigal’s fluency in designing MASH trials is a real asset for the siRNA program. If IND submission comes within 12 to 18 months, it signals that Madrigal is building a genuine RNA pipeline rather than holding an option. That filing date, not the nomination itself, is when the strategic weight of this deal becomes legible to competitors.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
